Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-23. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
=== Cold War === The GIUK gap again became the focus of naval planning in the 1950s, as it represented the only available outlet into the Atlantic Ocean for Soviet submarines operating from their bases on the Kola Peninsula. NATO worried that if the Cold War "turned hot", naval convoys reinforcing Europe from the U.S. would suffer unacceptable losses if Soviet submarines could operate in the North Atlantic. The United States and the United Kingdom based much of their post-war naval strategy on blocking the gap, installing a chain of underwater listening posts right across it during the 1950s – an example of a SOSUS "sound surveillance system". This deployment of sonar surveillance in the gap, and elsewhere, hampered the Soviet Northern Fleet's ability to deploy its submarines without detection. The Royal Navy's primary mission during the Cold War, excluding its nuclear deterrent role, involved anti-submarine warfare (ASW). The development of the Invincible-class ASW aircraft carriers stemmed from this doctrine: their primary mission involved anti-submarine warfare using Sea King helicopters. The Type 23 frigate originated as a pure ASW platform; its mission expanded following the Falklands War of 1982. The largest Russian submarine drills through the GIUK gap were operations Aport and Atrina, in 1985 and 1987, respectively, when the Soviets deployed several nuclear-powered general-purpose attack submarines (SSNs) near the U.S. coast before the 1985 Gorbachev–Reagan meeting.
== Mechanism of action == Levosimendan is a calcium sensitizer — it increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its positive inotropic effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner. It also has a vasodilatory effect, by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation. The combined inotropic and vasodilatory actions result in an increased force of contraction, decreased preload and decreased afterload. Moreover, by opening also the mitochondrial (ATP)-sensitive potassium channels in cardiomyocytes, the drug exerts a cardioprotective effect.
Urinary tract infection Skin infection Respiratory tract infection Odontogenic infection (an infection that originates within a tooth or in the closely surrounding tissues) Vaginal infections Intra-amniotic infection In addition, locations of inflammation where infection is the most common cause include pneumonia, meningitis and salpingitis.
Christopher Hitchens (13 April 1949 – 15 December 2011) was a British and American author, polemicist, debater and journalist who in his youth took part in demonstrations against the Vietnam War, joined organisations such as the International Socialists while at university and began to identify as a socialist. However, after 9/11 he no longer regarded himself as a socialist and his political thinking became largely dominated by the issue of defending civilization from terrorists and against the totalitarian regimes that protect them. Hitchens nonetheless continued to identify as a Marxist, endorsing the materialist conception of history, but believed that Karl Marx had underestimated the revolutionary nature of capitalism. He sympathized with libertarian ideals of limited state interference, but considered libertarianism not to be a viable system. In the 2000 U.S. presidential election, he supported the Green Party candidate Ralph Nader. After 9/11, Hitchens advocated for the invasion of Iraq. In the 2004 election, he very slightly favored the incumbent Republican President George W. Bush or was neutral and in 2008 he favored the Democratic candidate Barack Obama over John McCain despite being critical of both of them.
Sources: en.wikipedia.org
=== Involved pathways === Some of the pathways that have shown interaction in dedifferentiation are MSX1, Notch 1, BMP, and Wnt/β-catenin. MSx1, a gene that is a member of the homeobox family, encodes a transcriptional repressor that can prevent differentiation in epithelial and mesenchymal progenitor cell types. This repressor would be able to keep cells undifferentiated during development. Reduced levels of Msx1 expression resulted in an inability to regenerate tadpole tails. Bone morphogenic proteins (BMPs) are a group of signaling molecules involved in growth and development in many systems, including bone, embryogenesis, and homeostasis. The BMP pathway is necessary for dedifferentiation and regeneration in tadpoles. Downregulation of the BMP pathway led to a downregulation of MSx1, resulting in no regeneration in the tadpole. Once BMP expression was restored, Msx1 expression was also restored, and regeneration proceeded.19 Similar studies have shown similar results in mouse digit tip regeneration. The Notch1 pathway has demonstrated importance in the regeneration of frog tadpole tails. Notch1 is a gene in the Notch family of proteins. Notch proteins are part of an intercellular signaling pathway responsible for regulating interactions between cells that are physically next to one another by binding to other notch proteins.
18 January The ONS reports that inflation dropped for the second month running, to 10.5% in December, from 10.7% the previous month. At the two extremes of the ONS's list of "notable movements" that contribute to the overall figure, 'clothing and footwear' price inflation dropped from 7.5% to 6.4%, 'furniture and household goods' dropped from 10.8% to 9.8%, 'food and non-alcoholic beverages' rose from 16.5% to 16.9%, and 'restaurants and hotels' rose from 10.2% to 11.4%. BBC News reports that Church of England bishops will not give their backing to a change in teaching that would allow them to marry same-sex couples, but the Church will offer "prayers of dedication, thanksgiving or God's blessing" to gay couples. 19 January – Prime Minister Rishi Sunak apologises for taking his seat belt off in a moving car to film a social media clip. Lancashire Police later say they are "looking into" the incident. He is issued with a fixed-penalty notice the following day. 20 January The Church of England issues an apology for the "shameful" times it has "rejected or excluded" LGBTQ+ people, while Archbishop of Canterbury Justin Welby says he supports the changes that allow blessings to be offered to gay couples, but says he will not personally use them because he has a "responsibility to the whole communion". The High Court awards £39m in damages against Frimley Health NHS Foundation Trust in Surrey to a girl whose limbs were amputated after she was wrongly diagnosed.
React the peptide with a reagent that will selectively label the terminal amino acid. Hydrolyse the protein. Determine the amino acid by chromatography and comparison with standards. There are many different reagents which can be used to label terminal amino acids. They all react with amine groups and will therefore also bind to amine groups in the side chains of amino acids such as lysine - for this reason it is necessary to be careful in interpreting chromatograms to ensure that the right spot is chosen. Two of the more common reagents are Sanger's reagent (1-fluoro-2,4-dinitrobenzene) and dansyl derivatives such as dansyl chloride. Phenylisothiocyanate, the reagent for the Edman degradation, can also be used. The same questions apply here as in the determination of amino acid composition, with the exception that no stain is needed, as the reagents produce coloured derivatives and only qualitative analysis is required. So the amino acid does not have to be eluted from the chromatography column, just compared with a standard. Another consideration to take into account is that, since any amine groups will have reacted with the labelling reagent, ion exchange chromatography cannot be used, and thin-layer chromatography or high-pressure liquid chromatography should be used instead.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.